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ABSTRACT

A nonradioactive glass in particulate form adapted for
radiation therapy in a mammal comprise a biodegradable
rare earth-lithium borate glass material of a specified com
position which, upon being subjected to an effective amount
of neutron irradiation, will produce a beta or gamma emit
ting radioisotope, the radioisotope being distributed
throughout the glass material, the glass upon being intro
duced into a body fluid for radiation therapy being adapted
to react therewith causing the radioisotope to form an
insoluble compound on the surface of the glass material
which is retained in the glass material and thereby prevented
from escaping from the treatment site. Radioactive glasses
and methods for carrying out radiation therapy with such
radioactive glasses are also disclosed.
11 Claims, 7 Drawing Sheets

DISSOLUTION PRODUCTS / pH 7 . 4 )
HiBOs (*q)
Li * , LiOH (aq)
(OH)z(an)
AI0 /OH)Ua)t AfOg HgSi0$
UNDISSOLVED HYDRATES (pH 7. 4)
Re = Dy OR Ho

ION DIFFUSION

P043’ ,K+,N*+

DISSOLUTION PRODUCTS / p H 7, 4 )

U.S. Patent

ND
u

Apr. 30,2002

Sheet 1 of 7

US 6,379,648 B1

U.S. Patent

Apr. 30,2002

Sheet 2 of 7

US 6,379,648 B1

U.S. Patent

Apr. 30,2002

f V*

Sheet 3 of 7

US 6,379,648 B1

■1%

U.S. Patent

Apr. 30, 2002

Sheet 4 of 7

US 6,379,648 B1

U.S. Patent

Apr. 30, 2002

US 6,379,648 B1

Sheet 5 of 7

, 4 0 h
f '

*

.*

;

*

v<
.
■

B

i l l ^
M

p

p

p

M

l

j

W
*1 . «

v
M

»

B

«

I

: i l l i

M

S*
}
■■&r
-'r-'&o-i'
^

-

y

', 7 S h

6

: \ . >

-

‘

* • '

<124h

*

1€0h

U.S. Patent

Apr. 30,2002

Sheet 6 of 7

US 6,379,648 B1

U.S. Patent

Apr. 30,2002

Sheet 7 of 7

US 6,379,648 B1

US 6,379,648 B1
1

2

addition, alpha emitters are generally heavy metals, which
limits the possible chemistry and presents undue hazards
from leakage of radionuclide from the area to be treated.
It is fortuitous that beta emitters, the most useful radioBACKGROUND OF THE INVENTION
5 therapeutic radionuclides, are also the ones most copiously
produced by neutron capture in nuclear reactors, the most
This invention relates to radiation therapy such as radia
powerful sources of radioisotopes. Reactor-produced iso
tion synovectomy of arthritic joints and biodegradable glass
topes number in the thousands, giving researchers a wide
compositions in particulate form for use in radiation therapy.
choice of isotopes of various half-lives, beta energies,
Currently, no material for the in vivo delivery of thera
10 gamma emissions, and chemical properties. Gamma
peutic doses of beta radiation have been approved for use in
emissions, while not as useful as beta emissions, play an
important role in that they permit the distribution of radio
the United States for irradiation of diseased organs in the
isotope in the body to be observed using an Anger gamma
body, e.g. malignant tumors and the inflamed synovium of
ray camera or single photon computed tomography (SPECT)
arthritic joints. Materials that have been investigated previ
instrument. This permits direct observation and, to some
ously for in vivo radiotherapy can be classified as bio-inert
15
extent, quantification of radionuclide leakage from an organ
(non-degradable) glasses (e.g. Ehrhardt et al. Nuc. Med.
or a joint and also provides positive verification of the
Biol., 14 [3] (1987); Ehrhardt et al., Soc. of Nuc. Med., 39th
potency of joint injection and distribution of the radionu
Annual Meeting, June 9-12 (1992); Day et al., Advanced
clide in the research animal.
Series in Ceramics—Vol. 1, p. 305-317, World Scientific
With respect to radiation synovectomy of arthritic joints,
(1994); Hyatt et al., J. Am. Ceram. Soc., 70 [10] (1987); and
20 treatment of the different depths of diseased synovium in
Erbe et al., J. Biomed. Mat. Res., 27, 1301-1308 (1993)) or
joints of disparate size, such as the finger joints and the knee,
non-glasses (e.g. Ansell, Ann. Rheum. Dis., 6 Supp. 1-2
requires isotopes of different average beta range. It is
(1993); Ingrand, Ann. Rheum. Dis., 6 Supp. 3-9 (1973);
important to achieve a “kill” of sufficient depth to be
Boerbooms et al., Eur. J. Nuc. Med., 10 (1985); Spooren et
efficacious without causing significant necrosis of overlying
al., Eur. J. Nuc. Med., 10 (1985); and Neves et al., Appl.
25 normal tissues.
Rad. Isat., 38 [9] (1987)). All of these materials can be
Rare earth containing glass microspheres have been con
administered to the patient by injection in a similar fashion.
sidered for radiation synovectomy treatment of rheumatoid
Bio-inert radiotherapy glass particulates have already
arthritic joints. The radioactive glass microspheres could be
demonstrated the effectiveness of glass materials for safely
injected directly into the synovial sac and deliver enough
delivering large localized does of therapeutic beta radiation. 30 radiation ( = 10,000 rads (cGy)) to destroy the inflamed
However, such glasses are limited to therapies where the
lining of the diseased synovial membrane. Radiocolloid
particulates, e.g. 90Y or 198Au salts, are presently used in
glass can remain in the body indefinitely. Radiation syn
Europe for radiation synovectomy (e.g. Houle et al., Radi
ovectomy of diseased joints is one example of an application
ology 172 [3] 1989); Russel et al., Endocurietherapy/
where the eventual removal (clearance) of the radiopharma
ceutical may be desired. This creates the need for a biode 35 Hyperthermia Oncology, 4 [7] 171-186 (1988); Sledge et
al., Arth. Rheum. 29 [2] 153-159 (1986); Davis et al., J.
gradable material.
Nucl. Med., 30 [6] 1047-1055 (1989); Hall, Orthop. Clin.
Non-glass materials that have been proposed for use as
North Am., 6, 675-684 (1975); and Taylor et al., Ann.
radiopharmaceuticals include radiocolloids and ceramic,
Rheum. Dis., 31, 159-161 (1972)), but have not been
polymer or protein particulates that have a radioactive
approved for use in the United States because of unaccept
isotope attached (bonded) to their surface. Several of these 40 able amounts of radiation leakage during their use. The
non-glass materials can be cleared from in vivo treatment
radiocolloids are known to easily escape the synovium due
sites such as a rheumatoid arthritic joint. Each has
to their sub-micron size, and in certain instances 25% of the
shortcomings, however, that limits their usefulness and
targeted radiation has been deposited in healthy tissue out
safety during preparation and use. These shortcomings
side the joint. Glass microspheres for radiotherapy are much
include: ( 1 ) release of excessive or potentially dangerous 45 larger (>1 fim in diameter) than the radiocolloids and have
amounts of radiation outside the treatment site. This
the additional advantage of a carefully controlled size within
unwanted release has occurred due to the physical escape of
a few microns.
the intact radioactive materials, the disintegration of the
U.S. Pat. No. 5,011,797 dated Apr. 30, 1991 discloses
materials into smaller particles or ionic species while still
radioactive microspheres for radiation synovectomy of
radioactive, or the “debonding” of the radioisotope from the 50 arthritic joints which comprise a biodegradable glass mate
surface of a particle when in contact with body fluids; (2) the
rial and a beta radiation emitting radioisotope chemically
radiation dose is limited to amounts smaller than desired for
dissolved in and distributed substantially uniformly through
certain applications; (3) complex preparation procedures
out the glass material. The biodegradable glass material may
that include handling radioactive substances during fabrica
be lithium silicate, lithium aluminosilicate, lithium
tion; and (4) use of radioisotopes with a short half life, which 55 a l u m i n o b o r a t e , l i t h i u m g e r m a n a t e , l i t h i u m
means that the material must be used quickly. This limits the
aluminogermanate, potassium silicate, potassium
time available for distributing (mailing) the radiopharma
aluminosilicate, potassium aluminoborate, potassium ger
ceutical and causes other inconveniences.
manate or potassium aluminogermanate and the beta radia
tion emitting radioisotope may be samarium-153, holmiumBeta-emitting radionuclides are considered the most use
ful for radiotherapeutic applications because of the moderate 60 166, erbium-169, dysprosium-165, rhenium-186, rhenium188 or yttrium-90. The patent also discloses nonlinear energy transfer (LET) of the ionizing particle
biodegradable glass m aterials such as magnesium
(electron) and its intermediate range (typically several mil
aluminosilicate and aluminosilicate glass materials which
limeters in tissue). Gamma rays deliver dosage at lower
contain a beta radiation emitting radioisotope.
levels over much greater distances. Alpha particles represent
the other extreme; they deliver very high LET dosage, but 65
There is a continuing need for improved glass materials
have an extremely limited range and must, therefore, be in
adapted for radiation therapy such as radiation synovectomy
intimate contact with the cells of the tissue to be treated. In
of arthritic joints.
BIODEGRADABLE GLASS COMPOSITIONS
AND METHODS FOR RADIATION
THERAPY
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SUMMARY OF THE INVENTION

DyLAB-20 glass microspheres after immersion in PBS
solution (pH 7.4) at 37° C. for 24 hours. Shrinkage and
cracking on the surface of the DyLAB glass microspheres in
both (A) and (B) appeared after the spheres were removed
from solution. Notice the smooth surface texture of both the
glass and corrosion layer. White bar is 10 fim;
FIG. 4 shows representative photomicrographs (200x) of
the surface of a (A) DyLAB-5, (B) DyLAB-10, (C) DyLAB15, and (D) DyLAB-20 glass plate after immersion in PBS
solution (pH 7.4) for 11 days at 37° C. Evidence of a
corrosion (reaction) layer is seen (as cracks) in (A) and (B)
but not in (C) or (D). The edge of the DyLAB glass plate is
shown near the top of the photo in (C) and (D).
FIG. 5 shows chronological video images (220x) of a
group of DyLAB-10 glass microspheres after immersion in
PBS solution (pH 7.4) at 22° C. for the time (in hours)
shown in the upper left corner. The layer forming on the
outer surface of the glass microspheres becomes detectable
after about 26 hours and becomes progressively thicker with
time. The external diameter of the microspheres remains
nearly constant while the diameter of the unreacted core
becomes progressively smaller. The average diameter of the
microspheres was 28 fim;
FIG. 6 shows photomicrographs (A) 120x and (B) 480x
of DyLAB-10 glass microspheres (20-25 fim in diameter)
imbedded in a synovial membrane two weeks after injection
into the healthy stifle joint of a rat. The arrows in (A) point
to ( 1 ) the glass microspheres imbedded in the synovial
membrane; (2) the articular cartilage and (3) bone. Degra
dation of the glass microspheres is indicated in (B); a
corrosion layer ( 1 ) surrounds a glass core (2); and
FIG. 7 is a photomicrograph (480x) of (1) two DyLAB-10
glass microspheres engulfed by (2) macrophages (elliptical
shape) two weeks after injection into the healthy stifle joint
of a rat. Degradation of the microspheres is indicated by
discoloration at the surface and by a change in shape from
spherical to irregular.

Among the several objects of the invention may be noted
the provision of novel biodegradable rare earth-lithium
borate glass materials for use in radiation therapy; the
provision of such glass materials containing beta or gamma
emitting radioisotopes; the provision of such glass materials
in the form of microspheres; the provision of such biode
gradable glass materials which upon being introduced into a
body fluid for radiation therapy are adapted to react there
with causing the radioisotope contained therein to react with
the body fluid causing the radioisotope to form an insoluble
compound on the surface of the glass material which is
retained on the glass material and thereby prevented from
escaping from the treatment site; and the provision of
methods for carrying out radiation therapy such as radiation
synovectomy of arthritic joints. Other objects and features
will be in part apparent and in part pointed out hereinafter.
Briefly, the present invention is directed to novel radio
active glass in particulate form for radiation therapy in a
mammal comprising a biodegradable glass material having
one of the following compositions:

5

10

15

20

xRE20 3.(100-x)LiB30 5,
ARE20 3._vLi20.(100-A-v)B20 3,

25

ARE2O3._vMgO.(100-A-v)LiB3O5,
ARE2O3._vMgO.(100-A-v)Li2B8O13, and
xRE20 3.3M g0.5Si02_yAl20 3.(92-y-x)Li2B80 13

wherein RE is a neutron activatable rare earth which emits
a therapeutic intensity of beta or gamma radiation, the
radioisotope being distributed throughout the glass material,
x is the mole percent of RE20 3 and ranges between approxi
mately 0.5 and 5 and y is the mole percent of Li20 , MgO or
A120 3 and the balance is a lithium borate material glass. The
lithium borate glass is substantially free of lithium-6 and
boron-10 and the glass upon being introduced into a body
fluid for radiation therapy is adapted to react therewith
causing the radioisotope to form an insoluble compound on
the surface of the glass material which is retained in the glass
material and thereby prevented from escaping from the
treatment site.
Another aspect of the invention resides in the provision of
novel nonradioactive glass in particulate form which, upon
being subjected to an effective amount of neutron
irradiation, will produce a beta or gamma emitting radio
isotope thereby rendering the glass material suitable for use
for radiation therapy while avoiding the handling of radio
active elements during initial production of the glass mate
rial.
Still another aspect of the invention lies in the provision
of novel methods for carrying out radiation therapy such as
radiation synovectomy of arthritic joints utilizing the novel
radioactive glass material of the invention.
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic showing the formation of a corro
sion (reaction) layer on the surface of rare earth-lithium
borate glass microspheres as a result of non-uniform disso
lution;
FIG. 2 is a representative SEM photomicrograph of
dysprosium-lithium-aluminoborate (DyLAB) glass micro
spheres prepared by flame spheroidization. White bar is 10
fim;
FIG. 3 shows representative SEM photomicrographs of
(A) DyLAB-5, (B) DyLAB-10, (C)DyLAB-15, and (D)

60

DESCRIPTION OF THE PREFERRED
EMBODIMENTS
In accordance with the present invention, it has now been
found that a certain class of novel radioactive glass materials
in particulate form may be used for the in vivo irradiation of
diseased organs in the body, e.g. malignant tumors and the
inflamed synovium of arthritic joints. The glass materials
may be in the form of microspheres which, upon being
introduced into a body fluid for radiation therapy are adapted
to have the beta or gamma emitting radioisotope contained
therein react with the body fluid causing the radioisotope to
form an insoluble compound on the surface of the glass
material which is retained in the glass material and thereby
prevented from escaping from the treatment site to other
sites in the body. The radioactive glass materials of the
invention are prepared from novel nonradioactive glass
materials which may be manufactured, sized, and processed
in other ways before radioactivity is induced providing the
advantage of working only with nonradioactive materials
during initial production of the glass materials.
In a first embodiment of the invention, the novel radio
active materials in particulate form (e.g. microspheres) are
comprised of a biodegradable glass material having one of
the following compositions:
xRE20 3.(100- a)LiB 30 5

65

ARE20 3._vLi20.(100-A-v)B20 3
ARE2O3._vMgO.(100-A-v)LiB3O5

US 6,379,648 B1
5
xRE2O3.yMgO.(100-x-;y)Li.2B8O 13
xRE20 3.5 M g 0 .5 S i0 2.yAl20 3 (92-y-x)L i2B80 13

6
cant radioactivities induced by neutron bombardment will be
present after about one day of decay. Dysprosium-165,
yttrium-90, rhenium-186 and rhenium-188 and other beta or
gamma emitting radioisotopes may also be used as the
radioisotope in the practice of the invention.
Illustrative of the biodegradable lithium borate glass
materials within the above-noted compositions may be men
tioned the following:

wherein RE is a neutron activatable rare earth radioisotope
which emits a therapeutic intensity of beta or gamma 5
radiation and is distributed throughout the glass material, x
is the mole percent of RE20 3 and ranges between approxi
mately 0.5 and 5, y is the mole percent of Li20 , MgO or
A120 3 and the balance is a lithium borate glass material.
The lithium borate glass material is substantially free of 10
lithium-6 and boron-10. Lithium-6 is a 7.4% naturally
Dy20 3
1.7 mole %
abundant isotope which forms tritium when naturally occur
Li20
24.6 mole %
B20 3
73.7 mole %
ring lithium compounds are bombarded with neutrons. Tri
tium is a beta emitter with a half life of 12.5 years.
100.0 mole %
Accordingly, compounds which contain just lithium-7 15
Dy20 3
5 mole %
should be used since no radioactive isotopes are formed
Li20
16 mole %
a i 2o 3
5 mole %
when lithium-7 is bombarded with neutrons. Boron-10 is an
b 2o 3
66 mole %
isotope with a large thermal cross section, 3837 barns, which
s io 2
5 mole %
would be detrimental in a glass material of the present
MgO
3 mole %
invention because the glass might absorb so many neutrons 20
100
mole %
as to prevent other portions of the glass from becoming
Dy20 3
5 mole %
radioactive. This problem can be avoided by using com
Li20
15 mole %
pounds which contain only boron-11 that has a much smaller
a i 2o 3
10 mole %
thermal cross section, about 0.005 barns.
b 2o 3
62 mole %
S i0 2
5 mole %
Any neutron activatable rare earth radioisotope which 25
MgO
3 mole %
emits a therapeutic intensity of beta or gamma radiation may
be used in the practice of the invention as a component of the
100 mole %
above-noted glass material compositions. As used herein,
H o20 3
2 mole %
Li20
15 mole %
the term neutron activatable rare earth radioisotope includes
a i 2o 3
15 mole %
yttrium-90. Illustrative beta or gamma emitting radioiso 30
b 2o 3
60 mole %
topes include dysprosium-165, holmium-166, yttrium-90,
S i0 2
5 mole %
rhenium-186, rhenium-188 and samarium-153. These beta
MgO
3 mole %
or gamma emitting radioisotopes are particularly suitable for
100 mole %
use in the present invention. Samarium-153 (46.3 hr. halflife) and holmium-166 (26.8 hr. half-life) can be readily 35
dissolved in the above-noted glass compositions, have good
It will be understood that other radioisotope-containing
activation properties in a nuclear reactor, possess imageable
lithium borate glass materials within the above-noted com
gamma rays, exhibit low toxicity and have half-lives long
positions may also be used in the practice of the invention.
enough for distribution of the radioactive glass materials
As previously indicated, the biodegradable rare earthcontaining them.
40 lithium borate glass materials of the invention corrode, react
Holmium-166 is produced by neutron capture on 100%
or biodegrade in the body at controlled rates determined by
abundant, stable holmium-165 with thermal neutron and
the specific glass composition. This biodegradation occurs
resonance neutron cross sections of 61.2 and 67.0 barns,
in such a way that none of the beta or gamma emitting
respectively. It decays with a 26.83 hour half-life by emis
radioisotope contained in the glass escapes from the treat
sion of 1.855 MeV (51%) and 1.776 MeV (48%) maximum 45 ment site. Preferably, the glass materials are formed into
energy beta particles with a maximum range of about 8.0
microspheres of nearly any desired size, preferably micro
mm and an average range of about 2 mm. Since dysprosiumspheres having a diameter less than 100 microns and, more
165 emits a beta particle of slightly lower maximum energy
preferably, having a diameter between approximately 1 and
(1.31 MeV) and has proven efficacious in human knee
40 microns.
radiation synovectomies, it appears that holmium-166 has 50
After administration to the treatment site for radiation
sufficient penetration for this application. Ho-166 has suf
therapy as by injection or other suitable conventional means
ficient penetration for this application. Ho-166 also emits an
known to the art, the radioactive rare earth element either
80.5 Kev gamma ray in 6.2% abundance and thus is imagereacts with another constituent in the glass or with a body
able by conventional techniques.
fluid to form an insoluble compound on the surface of the
Samarium-153 is produced by neutron capture of natural 55 glass material, which insoluble compound may eventually
form throughout the glass material and be retained on the
or isotopically enriched samarium-152 with thermal and
glass material and is thereby prevented from escaping from
resonance neutron cross sections of 210 and 3,020 barns,
the treatment site. Referring to FIG. 1, there is shown a
respectively, it decays by beta emissions of 0.810 MeV
simplified model for the degradation or corrosion charac
(20%) 0.710 MeV (49%) and 0.640 MeV (30%) maximum
energies with concomitant ranges of about 2.3 mm maxi 60 teristics of dysprosium-165, holmium-166 or other rare earth
lithium borate glass microspheres of the invention as
mum and 0.8 mm average distance, respectively. Sm-153
employed for in vivo radiation therapy. FIG. 1 shows the
has a physical half-life of 46.27 hours and produces a highly
presence of a corrosion or reaction layer on the surface of the
imageable 103 KeV gamma ray with an abundance of
glass microsphere due to the dissolution of the B20 3, Li20 ,
29.8%, decaying to stable Eu-153.
Samarium-153 and holmium-166 are both chemically 65 MgO and, to a lesser extent, A120 3 and S i02. The insoluble
compound formed and retained on the glass material to
compatible and capable of being incorporated into the
prevent its unwanted migration to other sites may be, for
above-noted glass compositions in which no other signifi

US 6,379,648 B1
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example, a rare earth oxide, rare earth, hydroxide or rare
earth phosphate. Some of the probable products of dissolu
tion and undissolved Dy20 3 or Ho20 3, A120 3 and S i0 2 are
shown in FIG. 1. The diffusion of P, K and Na ions from
body fluids into the corrosion or reaction layer of the glass
microsphere is also indicated in FIG. 1. The undissolved
oxides in the corrosion layer may become partially hydrated.
As shown by the experimental work set forth hereinafter,
no measurable amount of radioactivity was released from
neutron activated DyLAB glass microspheres after being
immersed in deionized water at 37° C. for 11 hours. The lack
of release of dysprosium-165 from the radioactive DyLAB
microspheres was confirmed by similar measurements using
non-radioactive microspheres.
Degradation of the rare earth lithium borate glass mate
rials of the invention was observed during in vitro testing as
set forth hereinafter. The DyLAB glass microspheres shown
in FIG. 5 demonstrate the unique degradation characteristics
of the glass materials of the invention. Although none of the
radioactive component is released, the glass material began
to react within 24 hours in a PBS solution at 37° C. This is
shown in FIG. 5 as the formation of a rare earth rich reaction
layer on the DyLAB microspheres and indicates that the
glasses will be degradable in the body.
The degradation rate of the glass materials of the inven
tion can be easily controlled from approximately 10-6 to
10-10 g/cm2/min. by adjusting the glass composition. Thus,
the rare earth-lithium borate glasses of the invention can
safely accommodate a variety of useful radioisotopes (beta
or gamma emitters) whose half-life ranges from as little as
2 hours to as much as 7 days. This factor greatly enhances
the versatility of the glass materials of the invention for in
vivo radiotherapy.
The results of the in vitro studies and in vivo testing of the
glass materials of the invention set forth hereinafter are in
good agreement. A reaction or corrosion layer, similar to that
shown in FIG. 5, also formed on the glass microspheres that
were injected into the healthy stifle joints of a rat (see FIGS.
6 and 7). There was no detected difference between the
dissolution characteristics of the glass microspheres injected
into the joints of a rat and those immersed in simulated body
fluids.
The glass materials of the present invention, in the form
of microspheres, may be prepared from a homogeneous
mixture of powders (i.e. the batch) that is melted to form the
desired glass composition. The exact chemical compounds
or raw materials used for the batch is not critical so long as
they provide the necessary oxides in the correct proportion
for the melt composition being prepared. The mole and
weight percent of illustrative components of glass materials
of the invention are set forth in Tables II through V here
inafter. The purity of each raw material is typically greater
than 99.9%. After either dry or wet mixing of the powders
to achieve a homogeneous mixture, the mixture may be
placed in a platinum or platinum/rhodium alloy crucible for
melting in an electric furnace. The raw materials must not
contain impurities that become radioactive from neutron
irradiation.
After the crucible is removed from the furnace, the melt
is then cast into a bar or patty on a stainless steel plate. For
glass microsphere formation, the glasses are crushed with a
mortar and pestle to obtain glass powders. The powders are
then fed to a propane/air flame where each particle is melted
and spheroidized due to surface tension. The spherical
particles are cooled to solid glass microspheres and col
lected. The glass materials of the invention can be readily
made into microspheres of nearly any desired size, prefer
ably having a diameter of less than approximately 100
microns and, more preferably, a diameter between approxi
mately 1 and 40 microns.
The glass materials of the invention, in particulate form
such as microspheres, may be activated by being subjected

to an effective amount of neutron irradiation which will
produce a beta or gamma radiation emitting radioisotope
such as, for example, dysprosium-165, holmium-166,
yttrium-90, rhenium-186, rhenium-188 or samarium-153,
the amount depending upon the particular isotope of such
elements that has been chemically dissolved and uniformly
distributed throughout the glass materials. Since the glass
materials are made radioactive after they are fabricated, all
glass melting and fabrication into microspheres, for
example, advantageously involves only non-radioactive
materials.
As indicated, the radioactive glass compositions of the
present invention prepared as described may be adminis
tered for the in vivo irradiation of diseased organs such as
malignant tumors and the inflamed synovium of arthritic
joints. These novel glass compositions in the form of glass
microspheres, for example, may be administered by intraarticular injection or by other suitable means of administra
tion. When employed for radiation synovectomy of arthritic
joints, for example, the glass compositions are introduced
into synovial fluid, become distributed reasonably uniformly
in the synovial membrane to a depth of about 50 to 100
microns, and emit beta radiation to substantially fully irra
diate the thickness of the membrane without significant
dosage to more distant joint structures with the radioisotope
being retained in the glass material to prevent migration
from the treatment site.
The novel glass compositions of the present invention
offer the significant advantages of in situ degradability,
significantly decreased potential for radiation escaping from
the treatment site, and ease of preparation. Such glass
compositions also enable the use of larger radiation doses
than can currently be delivered by non-glass radiotherapy
materials, use relatively inexpensive materials and can be
delivered to essentially any site in the body by simple
injection. The nonradioactive glass compositions of the
invention also possess an indefinite shelf life.
The following examples illustrate the practice of the
invention.
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EXAMPLE 1
(1) Glass Preparation
The rare earth-lithium borate glasses listed in Table I,
containing either Dy20 3, Ho20 3, Y 20 3 or Sm20 3, were
prepared by melting a homogeneous mixture of analytical
grade powders of the rare earth oxides in a platinum or
platinum/rhodium alloy crucible in an electric furnace. All
bath materials used in glass preparation were oxides with the
exception of H 3B 0 3 and Li2C 0 3.
TABLE I

50

M ole Percent Composition of Rare Earth-LithiumBorate Glasses Investigated for Use as a Biodegradable
________________Radiopharmaceutical.________________
X
(r e 2o 3)*
(mole %)

Y
(mole %)

xD y20 3.(100 - x)LiB30 5
xD y20 3.yLi20 .(1 0 0 - x - y)B20 3
DyMLB

0.8-3.9
1.9-1.3

12.8-59.2

xD y2O 3.yMgO.(100 - x - y)LiB30 5
xD y2O 3.yMgO.(100 - x - y)Li2B80 13
DyLAB

1.7-3.8
3.9

1.6-24.5
9.0, 3.6

5.0

5-20

55
Glass Series
DyLB
60

65
5Dy20 3.3 M g 0 .5 S i0 2.yAl20 3.(87 - y)Li2B80 13

US 6,379,648 B1
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TABLE I-continued

TABLE III

M ole Percent Composition of Rare Earth-LithiumBorate Glasses Investigated for Use as a Biodegradable
________________Radiopharmaceutical.________________

Mole and W eight % Composition (wt % in
Parenthesis! of HoLB Glasses.

5
Glass

X
(r e 2o 3)*
(mole %)

Glass Series

HoLB-1

y

(mole %)
HoLB-2
10

HoLB

HoLB-3
0.5Ho20 3.yLi20.(100 - y)B20 3
HoLAB

0.5

2Ho2O3.3M gO.5SiO2.yAl2O3.(90 - y)Li2B80 13
YLAB

2.0

4.7-41.0
HoLB-4
5-20

HoLB-5
15
HoLB-6

5Y 2O3.3M gO.5SiO2.10Al2O3.77Li2B 8O 13
SmLAB

5.0

5Sm20 3.3 M g 0 .5 S i0 2.10Al20 3.77Li2B 80 13

5.0

—
HoLB-7
—

HoLB-8
20

*RE a Dy, Ho, Y, or Sm.

HoLB-9

Most of the glasses were melted between 1000 and 1150° C.
The melting temperature of the glasses which contained both
A120 3 and S i0 2 was slightly higher at 1200 to 1300° C.
Each melt was held at its melting temperature for approxi
mately 30 minutes (up to one hour for the RELAB glasses)
to assure complete melting and homogeneity. After this
period, the melts were stirred once with an alumina rod and
cast into a bar or patty on a stainless steel plate.

b 2o 3

Li20

Dy20 3

74.37
(83.11)
74.04
(80.93)
73.68
(78.73)
72.90
(74.33)
72.04
(69.92)
85.26
(84.46)
81.76
(82.76)
78.53
(81.28)
70.17
(76.77)
67.82
(75.43)
59.06
(70.00)
49.26
(62.96)
39.46
(54.77)

24.79
(11.89)
24.68
(11.58)
24.57
(11.27)
24.36
(10.66)
24.10
(10.04)
12.84
(5.46)
16.62
(7.24)
19.67
(8.74)
28.12
(16.21)
30.50
(14.56)
39.37
(20.03)
49.28
(27.04)
59.20
(35.27)

0.84
(5.00)
1.28
(7.49)
1.75
(10.00)
2.75
(15.01)
3.85
(20.04)
1.90
(10.08)
1.84
(10.00)
1.80
(9.98)
1.71
(10.02)
1.68
(10.01)
1.57
(9.97)
1.46
(10.00)
1.34
(9.96)

DyLB-2

DyMLB-1
35

DyMLB-2
DyMLB-3

DyMLB-5
40

Li20 /B 20 3 Glass Formation'

DyLB-3
DyLB-4
DyLB-5
DyLB-6
DyLB-7
DyLB-8
DyLB-9
DyLB-10
DyLB-11
DyLB-12
DyLB-13

H. Glass

(p)
H. Glass

0.33

DyMLB-8
45

(p)
H. Glass

(p)

0.10

H. Glass

(p)

0.20

H. Glass
0.30

(SQ)
S. Crystalline

0.35

(SQ)
H. Glass

0.40

(SQ)
H. Glass

0.45

(SQ)
M. Crystalline

0.50

(SQ)
P. Crystalline

0.70

(SQ)

Li20 / Glass
B 20 3 Formation*

b 2o 3

Li20

Dy20 3

MgO

73.43
(77.82)
70.69
(69.02)
68.92
(67.85)
65.74
(65.63)
59.65
(61.26)
53.96
(56.91)
70.49
(68.05)
74.75
(70.84)

24.22
(11.17)
23.67
(9.92)
23.03
(9.73)
21.96
(9.41)
19.94
(8.79)
18.00
(8.15)
16.65
(6.90)
17.70
(7.20)

1.74
(10.01)
3.83
(20.04)
3.79
(19.99)
3.74
(20.01)
3.63
(19.97)
3.54
(19.98)
3.87
(20.03)
3.94
(19.98)

1.61
(1.00)
1.80
(1.02)
4.26
(2.43)
8.56
(4.95)
16.78
(9.98)
24.50
(14.96)
8.98
(5.02)
3.61
(1.98)

H. Glass
0.33 (P)
H. Glass
0.33 (P)
H. Glass
0.33 (P)
H. Glass
0.33 (P)
H. Glass
0.33 (P)
H. Glass
0.33 (P)
H. Glass
0.24 (P)
H. Glass
0.24 (P)

(p)
H. Glass

0.33

H. Glass
0.05

30

DyMLB-4

0.33

Li20 /B 20 3 Glass Formation*

Mole and W eight % Composition (wt % in Parenthesis) of
DvMLB Glasses.

DyMLB-7
DyLB-1

0.05
(2.73)
0.50
(2.80)
0.50
(2.93)
0.50
(3.05)
0.50
(3.10)
0.50
(3.16)
0.50
(3.21)
0.50
(3.26)
0.50
(3.44)

TABLE IV

DyMLB-6
Glass

Dy20 3

4.70
(2.03)
9.00
(3.98)
16.60
(7.68)
23.00
(11.08)
25.80
(12.66)
28.40
(14.17)
30.90
(15.68)
33.20
(17.11)
41.00
(22.33)

25

TABLE II
M ole and W eight % Composition (wt % in
______ Parenthesis) of DyLB Glasses.______

Li20

*(P) = Cast on steel plate; (SQ) = Splat quenched between steel plates; H
= Homogeneous; S = Slightly; P = Partly; M = M ostly

Glass

The glasses were stored in a desiccator until they were
annealed for property measurements or crushed for spheroidization. The batch composition of the rare earth-lithium
borate glasses are listed in Tables II through V.

b 2o 3

94.80
(95.25)
90.50
(93.23)
82.90
(89.39)
76.50
(85.87)
73.70
(84.24)
71.10
(82.67)
68.60
(81.11)
66.30
(79.63)
58.50
(74.23)

* H = Homogeneous; (P) = cast on steel plate.

(p)
H. Glass

0.33

(p)
H. Glass

0.33

(p)

TABLE V
50
Mole and W eight % Composition (wt % in Parenthesis) of
RELAB Glasses* * IRE = Dv. Ho. Y. or Sml.

H. Glass
0.15

(p)
H. Glass

0.20

(p)
H. Glass

0.25

(p)
H. Glass

0.40

(p)
H. Glass

0.45

(p)
P. Crystalline

0.67

(SQ)
P. Crystalline

1.00

(SQ)
P. Crystalline

1.50

(SQ)

*(P) = Cast on steel plate; (SQ) = Splat quenched between steel plates; H
= Homogeneous; S = Slightly; P = Partly

S i0 2

Glass
Formation*

55 Glass

B20 3

Li20

RE20 3

A120 3

M gO

DyLAB5
DyLAB60
10
DyLAB15
DyLAB65 20
Ho-

66
(58.39)

16
(6.08)

5
(23.70)

5
(6.48)

3
(1.54)

5
(3.82)

H.
Glass

62
(53.48)

15
(5.55)

5
(23.11)

10
(12.63)

3
(1.50)

5
(3.72)

H.
Glass

58
(48.81)

14
(5.06)

5
(22.55)

15
(18.49)

3
(1.46)

5
(3.63)

H.
Glass

54
(44.37)

13
(4.58)

5
(22.01)

20
(24.07)

3
(1.43)

5
(3.55)

H.
Glass

(p)
(p)
(p)
(p)
68

17

2

5

3

5

H.

US 6,379,648 B1
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TABLE V-continued
M ole and W eight % Composition (wt % in Parenthesis) of
______ RELAB Glasses * * (RE = Dy, Ho, Y, or Sm).______

S i0 2

5

Glass
Formation*

Glass

B20 3

Li20

r e 2o 3

a i 2o 3

MgO

LAB5
HoLAB10
HoLAB15
HoLAB20
YLAB10
SmLAB10

(68.22)

(7.33)

(10.91)

(7.36)

(1.75)

(4.34)

Glass

64
(32.49)

16
(6.71)

2
(10.60)

10
(14.30)

3
(1.70)

5
(4.21)

(p)
H.
Glass

60
(56.97)

15
(6.11)

2
(10.31)

15
(20.86)

3
(1.65)

5
(4.10)

(p)
H.
Glass

56
(51.75)

14
(5.55)

2
(10.03)

20
(27.07)

3
(1.61)

5
(3.99)

(p)
H.
Glass

66
(58.85)

16
(6.11)

5
(15.39)

10
(13.90)

3
(1.65)

5
(4.10)

(p)
H.
Glass

62
(54.30)

15
(5.64)

5
(21.94)

10
(12.83)

3
(1.52)

5
(3.78)

(p)
H.
Glass

10

15

20

(p)

*H = Homogeneous; (P) = cast on steel plate.
**Li20 /B 20 3 = 0.24 for all RELAB glasses.
fT h e number included in the glass ID corresponds to the mole % A120 3 in
the glass (For the RELAB glasses only).

(2) Property Measurements
The density of the glasses at 25° C. was measured by
Archimedes’ buoyancy method using kerosene as the sus
pension medium whose density (0.8015 g/cm2 at 25° C.)
was determined using a Gay-Lussac specific gravity bottle.
For density measurement, the dry and suspended mass of a
crack-and bubble-free piece of each annealed glass was
measured on an analytical balance. The experimental error
in the density was estimated to be ±0.01 g/cm2.
The nD refractive index was measured by the Becke line
method using certified refractive index liquids and a filter
which transmitted only sodium D(589 nm) light. Annealed
glasses that were crushed with a porcelain mortar and pestle
were used for the refractive index measurement. The error
for the refractive index was ±0.002.
(3) Chemical Durability Measurement
The chemical durability of the glasses that contained
Dy20 3 or Ho20 3 was evaluated by measuring the weight
loss of as-cast or annealed bulk glass samples that were
immersed in phosphate buffered saline (PBS) solution (pH
7.4) at 37° C. PBS solution at 37° C. was used as the
corrosion medium to simulate both the ion content, listed in
Table VI, and temperature of body fluids, e.g. synovial fluid.
TABLE VI
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Molar Content of Inorganic Electrolytes in
Phosphate Buffered Saline (PBS) Solution Used in Corrosion Testing
of RELAB Glasses.
Species

Mole/liter x 10 3 (mM)

Na+
K+
CL
H2P 0 47 H P 0 42-

153.1
4.2
139.6
9.6

55

60

The as-cast samples for corrosion testing were selected from
pieces of the DyLB, HoLB, DyMLB, DyLAB or HoLAB
glasses that were free of cracks or thin, pointed edges.
Rectangular glass samples (plates) for corrosion testing
were cut from annealed DyMLB and DyLAB glasses and
polished to a 0.05 fim surface finish using SiC paper and
A120 3 polishing abrasive. Only non-aqueous lubricants, i.e.

65

kerosene and mineral oil, were used during the cutting and
polishing to avoid corrosion of the glass before testing. Any
residual kerosene or mineral oil was removed from the glass
surface prior to testing by rinsing the plates with acetone.
Glass plates (=10x5x2 mm) were used so that the dissolution
rate (DR in g/cm2/min.) could be calculated from the weight
loss of the glass. Prior to immersion in the PBS solution, the
surface area of the DyMLB and DyLAB glass plates was
estimated from their bulk dimensions, and the initial weight
of all the glass samples was determined.
The bulk glass samples (as-cast pieces or annealed glass
plates) were immersed separately in approximately 100 ml
of PBS solution at 37° C. that was contained in high density
polyethylene (HDPE) bottles. The glass samples were peri
odically removed from the PBS solution, gently rinsed with
acetone to remove any residual PBS, and dried in air at 70°
C. for at least 30 minutes. After drying, the reacted or
corroded glass samples were weighed and placed back into
their respective PBS solution for further testing. These steps
were repeated several times for up to 18 days (or 75 and 90
days for the DyLAB and HoLAB glasses respectively).
Inductively coupled plasma spectroscopy (ICP) was used
to measure the amount of Dy, if any, released from the DyLB
and DyMLB glass samples after immersion in the PBS
solution at 37° C. for 5 or 24 hours. Approximately 10 ml of
the PBS solution from each glass sample was decanted and
replaced with fresh solution. The decanted PBS solution was
filtered to remove any particulates and analyzed by ICP to
determine the Dy concentration. Note that within 5 and 24
hours, 77.8 and 99.9% of radioactive 165Dy, respectively,
decays to its non-radioactive daughter, 165Ho.
(4) Glass Microsphere Preparation
The feasibility of preparing glass microsphere for in vivo
use from rare-earth lithium borate glasses was tested using
the flame spheroidization technique. Flame spheroidization
was attempted using at least one of each of the DyLB,
HoLB, DyMLB, DyLAB and HoLAB glass compositions
from Table I above. Each glass was crushed with a porcelain
mortar and pestle and sieved to obtain a -45 fim (-325
mesh) powder. The glass powder was slowly dropped into a
propane/air flame, via a vibrating spatula located above the
flame, where each particle became molten and was drawn
into a sphere by surface tension. Upon exiting the flame, the
spherical droplets cooled to a glass and were collected in a
stainless steel cylinder.
RESULTS
(1) Rare Earth-Lithium Borate Glass Formation
Each rare earth-lithium borate glass batch completely
melted and become bubble-free after being held at its
respective melting temperature (1000 to 1300° C.) for a few
minutes. All of the glass melts were noticeably more fluid
than molten B20 3 or most glass forming silicate melts. The
viscosity of a typical soda-lime-silicate glass at its “melting”
temperature, 1450° C., is 10 to 100 poise. The low viscosity
of the rare earth-lithium borate glass melts is an advantage
since it aids homogenization of the melt and decreases the
time needed for fining which limits any loss of the more
volatile elements such as boron and lithium. There was no
evidence of volatilization from the rare earth-lithium borate
melts, except for slight fuming that was only observed for
the Dy-LAB-20 melt that was melted at 1300° C.
Most of the DyLB and HoLB and all of the rare earthlithium borate glasses that contained A120 3, MgO and
and/or S i0 2 (DyMLB, DyLAB, HoLAB, YLAB and
SmLAB) formed a clear glass when cast on a steel plate, as
indicated in Tables II through VI. The rare earth-lithium
borate glasses contained some striae but otherwise appeared
homogeneous. All of the rare earths, except Y, resulted in
colored glass, orange for Ho and yellow for Dy or Sm.

US 6,379,648 B1
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(2) Density and Refractive Index
The density of the rare earth-lithium borate glasses ranged
from 2.29 to 2.95 g/cm3 and increased linearly with increas
ing mole % Re20 3.
The refractive index (n^,) of the rare earth-lithium borate 5
glasses ranged from 1.544 to 1.604 and increased with
increasing mole % rare earth oxide, which was expected
from the increase in density. However, fluctuations in the
refractive index due to the addition of A120 3 or MgO were
more pronounced than those for the density of the rare 10
earth-lithium borate glasses.
(3) Chemical Durability to the Rare Earth-Lithium Borate
Glasses
The chemical durability of a rare earth-lithium borate
glass is important from the standpoint of both unwanted 15
radiation leakage and eventual disintegration and dissolution
of the glass. The rare earth-lithium borate glass micro
spheres should preferably completely retain the rare earth
radionuclide within the treatment site while it is still sig
nificantly radioactive, which is approximately one, 11 , 20 or 20
27 days (i.e. 10 half-lives) for 1(” Dy, 166Ho, 90Y, or 153Sm,
respectively. Ten half-lives correspond to the time when
99.9% of the radiation has decayed, at which point the rare
earth-lithium borate glass microspheres could completely
disintegrate without releasing harmful amounts of radiation. 25
(a) Release of Dy
No detectable amount of Dy (=0.1 ppm) was found by
ICP analysis in any of the PBS solutions that were in
contact with the DyLB (1 through 5) or DyMLB
glasses for 5 to 24 hours at 37° C. These results were
confirmed by testing two additional samples of each
DyMLB glass.
(b) Weight Loss and Dissolution Rate
The chemical durability of the rare earth-lithium borate
glasses varied drastically with composition, and gen
erally increased with increasing mole % rare earth
oxide. The weight loss and dissolution rate (DR) for the
DyLB and DyMLB glasses after 8 days and the
DyLAB and HoLAB glasses after 7 days are listed in
Tables VII and VIII, respectively.
Overall, the HoLB and DyLB glasses were the least
durable rare earth-lithium borate glasses. The DyLB-1
through DyLB-5 glasses, which contained from 0.84 to 3.9
mole % Dy20 3, respectively, were more durable than the
HoLB glasses and did not fully react within 24 hours. As a
whole, the DyMLB glasses were slightly more durable than
the DyLB glasses and had from 1.0 to 13.7% weight loss
after immersion in the PBS solution at 37° C. for 8 days (see
Table VII).
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Percent W eight Loss and Dissolution Rate for
DyLB, DyALB, and DyM LB Glasses (Mole % D y2Os and A120 3 or
_______________ M gO are included for Comparison.________________
55
Glass
DyLB-1
DyLB-2
DyLB-3
DyLB-4
DyLB-5
DyMLB-1
DyMLB-2
DyMLB-3
DyMLB-4
DyMLB-5
DyMLB-6

0.84
1.28
1.75
2.75
3.85
1.77
3.83
3.79
3.74
3.63
3.54

0
0
0
0
0
1.61
1.80
4.26
8.56
16.78
24.50

% W eight Loss
± 0 .2 % *

DR±23 x 10-8
(g/cm2/min.)*

24.5
21.8
14.3
7.9
2.5
7.9
3.3
5.4
8.1
4.4
4.8

nm
nm
nm
nm
nm
nm
nm
nm
89
63
90

Percent W eight Loss and Dissolution Rate for
DyLB, DyALB, and DyM LB Glasses (Mole % D y2Os and A l2Os or
________________ M gO are included for Comparison.________________

Glass
DyMLB-7
DyMLB-8

M ole %
M ole %
D y20 3 A l2Os or M gO
3.87
3.94

% W eight Loss
± 0 .2 % *

8.98
3.61

1.0
2.4

D R±23 x K T 8
(g/cm2/min.)*
20
73

*After =8 days (200 hours) in PBS solution at 37° C.
(nm) not measured

TABLE VIII
Percent W eight Loss and D issolution Rate for
DyLAB and HoLAB Glasses (Mole % RE2Os and A l2Os are included for
____________________________ Comparison).____________________________

Glass
DyLAB-5
DyLAB-10
DyLAB-15
DyLAB-20
HoLAB-10
HoLAB-15
HoLAB-20
YLAB-10
SmLAB-10

M ole % M ole % % W eight Loss
r e 2o 3
a i 2o 3
± 0 .005 % *
5.0
5.0
5.0
5.0
2.0
2.0
2.0
5
5

5
10
15
20
10
15
20
10
10

2.740
0.040
0.003
(nd)
4.866
0.822
(nd)
nm
nm

DR± 0.1 x 10~8
(g/cm2/min.)*
173.3
2.7
0.1§
(nd)
461.0
21.2
(nd)
nm
nm

30 f RE = Dy, Ho, Y or Sm
(nm) not measured.
*After =7 days in PBS solution 37° C.
^Measured w eight loss was within the calculated experimental error.
(nd) No detectable w eight loss (±0.05 mg uncertainty).

TABLE VII

M ole %
M ole %
D y20 3 A120 3 or MgO

TABLE VH-continued
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The DR of the DyMLB glasses (listed in Table VII) was
the same order of magnitude ( 10-2 g/cm2 min.) for all the
glasses but, like the percent weight loss, was somewhat
inconsistent with differences in composition.
The DyLAB glasses were generally much more chemi
cally durable than the DyLB or DyMLB glasses, which was
not surprising since the DyLAB glasses had the highest
Dy20 3 content (5 mole %) and contained S i02, A120 3 and
MgO. The HoLAB glasses contained less rare earth (2 mole
% Ho20 3) than the DyLAB glasses and were, consequently,
less chemically durable. The DyLAB-15, DyLAB-20 and
HoLAB-20 glasses, which lost little or no weight in the PBS
solution at 37° C. are clearly the least degradable of the rare
earth-lithium borate glasses.
(4) Rare Earth-Lithium Borate Glass Microsphere Pabrication
Solid glass microspheres (1 to 40 fim in diameter) were
successfully prepared from all of the DyLAB and HoLAB
glasses and the DyLB-3, DyLB-8, DyMLB-6, DyMLB-8
and HoLB-5 glasses. The microspheres made from the
DyLAB-5 glass exhibited uniformity and smooth surfaces
representative of all the rare earth-lithium borate micro
spheres prepared by flame spheroidization. A small fraction
of the rare earth-lithium borate glass microspheres contained
one or more small gas bubbles which should not have any
adverse effect on the use of the microspheres for radio
therapy.
EXAMPLE 2
(1) Glass Preparation
Pifty grams of each of the dysprosium and holmium
glasses listed in the following Table IX were prepared by
melting a homogeneous mixture of high purity powders (i.e.
Dy20 3, H3B 0 3, Li2C 03, A120 3, S i0 2 and Mgo) in a plati
num or platinum/rhodium alloy crucible in an electric fur
nace.

US 6,379,648 B1
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TABLE IX
M ole % Composition of the DyLAB and HoLAB Glasses
Investiaated for In Vivo Radiotherapy.
Glass*
DyLAB-5
DyLAB-10
DyLAB-15
DyLAB-20
HoLAB-10
HoLAB-15
Ho LAB-20

r e 2o 3**

Li20

a i 2o 3

5(23.7)
5(23.1)
5(22.6)
5(22.0)
2(10.6)
2(10.3)
2(10.0)

16
15
14
13
16
15
14

5
10
15
20
10
15
20

b 2o

66
62
58
54
64
60
56

3

5

S i0 2

Mgo

5
5
5
5
5
5
5

3
3
3
3
3
3
3

*The number in each Glass ID corresponds to the mole % A120 3 in the
glass.
**Dy20 3 (DyLAB) or H o20 3 (HoLAB). Weight % in parenthesis.

All batch materials used to prepare the glasses were oxides
except H3BO3 and Li2C 03. Each batch melted completely
and was mostly bubble free between 1200 and 1300° C. after
less than 30 minutes. The viscosity of the melts was much
lower than that of soda-lime glass (10 to 100 Poise at -1500°
C.). Each melt was held at its melting temperature for
approximately one hour before being stirred with an alumina
rod and then cast into a bar or patty on a stainless steel plate.
A portion of each dysprosium glass was annealed in air at
500° C. for 30 minutes. The annealed dysprosium glasses
were inspected for any residual stress by viewing them
through cross polarized light.
(2) Glass Microsphere Formation
For glass microsphere formation, the glasses were
crushed with a porcelain mortar and pestle and the particles
were sieved to obtain a -45 fim (-325 mesh) glass powder.
The glass powder was then fed to a propane/air flame where
each particle melted and spheroidized due to surface tension.
Upon exiting the flame, the spherical particles cooled to
solid glass microspheres and were collected in a large
stainless steel cylinder (barrel). Microspheres were prepared
from each glass listed in Table IX above. After
spheroidization, the glass microspheres were dry sieved to
size ranges of +38, -38/+32, -32/+25, -25/+20, and -20 fim
in diameter and then stored in a desiccator.
(3) Chemical Durability Measurements
(A) Weight Loss.
For corrosion testing of bulk dysprosium and holmium
glasses, rectangular samples (plates) were cut from the
annealed dysprosium glasses, and an as-cast piece of
each holmium glass was selected. The dysprosium
glass plates were polished to a 0.05 fim finish using SiC
paper and A120 3 polishing abrasive. Only non-aqueous
lubricants were used during cutting and polishing to
minimize potential corrosion of the glass before testing.
The lubricants were removed from the glass surface by
washing the samples in acetone. The weight and sur
face area of the bulk dysprosium and holmium glass
samples were measured prior to corrosion testing.
Since the holmium glass samples were not rectangular,
their surface area was only an estimate.
The bulk dysprosium and holmium glass samples were
corroded separately using phosphate buffered saline
(PBS) solution (pH 7.4) at 37° C. in high density
polyethylene bottles. The PBS solution (Sigma Chemi
cal Co., St. Louis, Mo.) was used since its pH and
inorganic ion content is very close to that of fluids in
the body. The glass surface area to solution volume
(SA/V) ratio for each glass sample was approximately
0.1 cm-1. Periodically, the glass samples were removed
from the PBS solution, briefly submerged in acetone to
remove any residual PBS, and dried in air at 70° C. for
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30 minutes. The glass samples were then weighed and
immediately replaced in their respective PBS solution
for further testing. These steps were repeated several
times for up to 90 days. The dissolution rate (DR in
g/cm2/min.) of each dysprosium and holmium glass for
a given period was determined by dividing the weight
loss by the initial surface area and elapsed dissolution
time.
(B) Solution Analysis.
Inductively coupled plasma spectroscopy (ICP) or scin
tillation counting of leached radioactive 165Dy were
used in two separate experiments to quantify the
amount of Dy3+, if any, that dissolved from the abovenoted DyLAB glass microspheres during corrosion. For
ICP analysis, approximately 70 mg of non-radioactive
DyLAB-5, DyLAB-10, DyLAB-15 or DyLAB-20
glass microspheres (28±4 fim average diameter) were
corroded in 30 ml of PBS solution at 37° C. (estimated
SAW -1 .8 cm-1) for 5 or 24 hours. In one case, ICP was
used to analyze the PBS solution that had been in
contact with DyLAB-10 glass microspheres for 23
days. After submersion for 5 or 24 hours (or 23 days),
the glass microspheres were vacuum filtered from the
PBS solution and examined by scanning electron
microscopy (SEM). Each PBS solution was analyzed
by ICP to determine the amount of Dy and other glass
components, i.e. B, Al, Si and Mg, in solution. The ICP
equipment used had a lower detection limit of 0.1 ppm
for Dy, B, Al, Si and Mg.
The radioactivity of deionized (DI) H20 in which neutron
activated DyLAB-10 or DyLAB-20 glass microspheres
were immersed at 37° C. (estimated SA/V~cm-1) was
measured to determine the amount of radioactive 165Dy
in solution. Approximately every three hours, V2 of each
test solution was removed and replaced with an equal
volume of fresh DI H20 . The decanted test solution
was filtered to eliminate any glass microspheres and
then analyzed by counting the 94 KeV gamma emis
sions of 165Dy. The radioactivity of the DyLAB glass
microspheres was also measured as a control.
(C) Surface Analysis.
Electron dispersion spectroscopy (EDS) and x-ray pho
toelectron spectroscopy (XPS) were used to determine
the surface composition of as-made and corroded
DyLAB glass plates. Of most interest was the concen
tration of Dy in the corroded surface of the DyLAB
glasses as compared to the as-made glass. EDS analysis
was performed on the same DyLAB-5 glass plate that
had been corroded for the weight less measurement.
For XPS analysis, a separate set of DyLAB-10 glass
plates were corroded in PBS solution at 37° C. for 0, 5,
24 or 336 hours (2 weeks).
(D) In-Vivo Testing of Glass Microspheres.
A preliminary investigation of the in vivo chemical dura
bility and biocompatibility of the glass microspheres
was made by injecting non-radioactive DyLAB-10
glass microspheres directly into the healthy stifle joint
(knee) of a rat. The DyLAB-10 glass microspheres (20
to 25 fim in diameter) were suspended in a 75 wt. %
glycerol-saline solution (0.04 mg of spheres/wl) prior to
injection. The glycerol was used to increase the vis
cosity of the carrier liquid so that the glass micro
spheres remained suspended for injection. Fifty and
100 fi\ of the above suspension, i.e. 2 and 4 mg of
DyLAB-10 glass microspheres (roughly 50,000
spheres/mg) were injected into the left and right stifle
joint, respectively.
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The animal was sacrificed two weeks after injection of the
% A120 3, which is attributed to the difference in the amount
(5 or 2 mole % Dy20 3 or Flo20 3, respectively) rather than
glass microspheres and thin tissue sections were pre
to the specific rare earth oxide. The mole % Dy20 3 or Flo20 3
pared from each stifle joint. For preparation of the
was held constant within each RELAB glass series, DyLAB
tissue sections, the joints were removed from the rat,
dehydrated, and fixed in polymethylmethacrylate. Thin 5 or FloLAB, in order to standardize the neutron activation
time and the resulting specific activity of the RELAB glass
sections were cut from the fixed joints, along the
microspheres. The chemical durability of the DyLAB and
sagittal plane, and polished using SiC paper and A120 3
FloLAB glasses was controlled by adjusting the A120 3
polishing abrasive. The polished sections were exam
content which would have no effect on the neutron activation
ined by optical microscopy to determine the physical
time.
condition of the DyLAB-10 glass microspheres and the
10
(3) Release of Dysprosium from DyLAB Glass Micro
surrounding synovial tissue and any evidence of tissue
necrosis or other adverse responses.
spheres
No measurable amount of radioactivity (sub-nCi detec
RESULTS
tion limit) was released from neutron activated DyLAB-10
(1) Rare Earth Glass Formation
All of the dysprosium and holmium melts cooled to a 15 or DyLAB-20 glass microspheres immersed in deionized
water at 37° C. for up to 11 hours (i.e. 4.8 half-lives for
clear glass that was free of bubbles and unmelted batch
165Dy during which 96.4% of the radiation decays). The
material. The dysprosium and holmium glasses were yellow
absence of any detectable radiation in the deionized water is
or orange in color, respectively, and contained some striae,
important evidence that no radiation would be released
but were otherwise homogeneous in appearance. Residual
outside the treatment site and supports the safety of using
stress in the dysprosium glasses was adequately removed by
20 DyLAB glass microspheres in vivo. Furthermore, these
annealing the glasses at 500° C. in air for 30 minutes.
results demonstrate that neutron activation does not
Microspheres were successfully produced from each of
adversely affect the chemical durability of the DyLAB glass
the dysprosium and holmium glasses, and all were alike in
both their formation qualities and appearance. The repre
microspheres. The lack of Dy release from the radioactive
sentative photomicrograph in FIG. 2 shows the uniformity
DyLAB glass microspheres was confirmed by similar mea
and smooth surface texture of the glass microspheres that 25 surements using nonradioactive microspheres.
were prepared by flame spheroidization. Although not vis
The ICP analysis of the PBS solution that was in contact
ible in FIG. 2, a small fraction of the glass microspheres
with the DyLAB glass microspheres at 37° C. indicates that
contained one or more gas bubbles.
the weight loss of the glass was due to dissolution of the
(2) Dissolution Rate of Dysprosium and Flolmium Glasses
non-activatable glass components and not to the dissolution
The cumulative percent weight loss per surface area
of Dy. No measurable amount of Dy (>0.1 ppm) was
30
(%WL/cm2) of the bulk dysprosium (5 mole % Dy20 3) and
detected by ICP analysis of the PBS solution that had been
holmium (2 mole % Flo20 3) glass samples after immersion
in contact with DyLAB-5, DyLAB-10, DyLAB-15 or
in PBS solution at 37° C. for 1, 7 or 75 days (90 days for
DyLAB-20 glass microspheres at 37° C. for up to 24 hours.
holmium glasses is listed below in Table X.
This is significant since in 24 hours, 99.9% of the 165Dy
decays to its non-radioactive daughter isotope 165F1o. In
35 other words, no detectable amount of radioactive 165Dy
TABLE X
would be released in the first 24 hours. Dysprosium was
Percent W eight Loss Per Surface A rea for DyLAB and
likewise not detected in the PBS solution that contained
HoLAB Glasses Corroded in PBS Solution at 37° C. (SA/V = 0 .1 cm "1).
DyLAB-10 glass microspheres for 23 days.
Although there was no evidence that any Dy was dis
Glass
ID
% W L/cm 2 ± 0.001
40 solved from the DyLAB glass microspheres, detectable
amounts of B, Al, Si and Mg were dissolved from the
24 h
7 d
75 d
microspheres of each DyLAB glass. The amount of specific
glass components that dissolved from the DyLAB glass
DyLAB-5
0.035
0.258
1.163
microspheres decreased with increasing mole % A120 3 in
DyLAB-10
0.007
0.009
0.166
4=4=
4=4=
DyLAB-15
O.OOlf
45 the glass, i.e. the overall corrosion resistance of the DyLAB
4=4=
4=4=
4=4=
DyLAB-20
glass microspheres increased with increasing A120 3 content,
which
was also true for the bulk DyLAB glass plates (see
24 h§
7 d§
90 d§
Table X).
4=4=
As has been shown, the RELAB glasses do not dissolve
HoLAB-10
4.443
33.532
4=4=
HoLAB-15
0.204
2.200
uniformly and none of the radioactive rare earth, including
4=4=
4=4=
50
HoLAB-20
0.189
166F1o, 90Y or 153Sm, would be expected to be released from
RELAB glass microspheres. Non-uniform dissolution of the
** -No detectable w eight loss (±0.05 mg uncertainty).
RELAB glass microspheres where the rare earth radionu
f-M easured w eight loss within calculated experimental error.
clide is retained in the glass is clearly an advantage for safe
§-Calculated from estimated surface area.
in vivo radiotherepy, especially for glasses that contain the
The weight loss results show that the chemical durability of 55 longer-lived 166Ho, 90Y or 153Sm.
the glasses varied significantly, increasing with increasing
(4) Formation of a Dy Rich Reaction Layer
A120 3 (5 to 20 mole %). For instance, the DyLAB-5 and
Several techniques were used to verify the formation of a
DyLAB-10 glass plates (5 and 10 mole % A120 3,
Dy rich reaction layer on the surface of the DyLAB glass
respectively) had a total weight loss of 1.16 and 0.17%/cm2
plates and microspheres that were immersed in PBS at 37°
after 75 days, respectively, whereas the DyLAB-15 and 60 C.
(A) SEM and Optical Microscopy
DyLAB-20 glass plates (15 and 20 mole % A120 3,
SEM and optical microscopy show that a visible reaction
respectively) had little to no measurable weight loss.
layer formed on both the microspheres and plates of
Likewise, the weight loss of the FloLAB glass plates after 90
DyLAB-5 and DyLAB-10 glass that were immersed in
days decreased from 33.53 to 0.19%/cm2 as the A120 3
65
PBS solution. SEM photomicrographs of the DyLAB-5
content increased from 10 to 20 mole %.
and DyLAB-10 glass microspheres after 24 hours in
The DyLAB glasses were clearly more chemically
durable than the FloLAB glasses that contained equal mole
PBS at 37° C. (FIGS. 3(a) and 3(b)) show cracking and

US 6,379,648 B1
19

20

partial separation of a layer from the microsphere
was first noticed after approximately 5 and 26 hours for
surface. The cracks on the surface of the DyLAB glass
the DyLAB-5 and DyLAB-10 glass microspheres,
microspheres appeared when the spheres were dried,
respectively, and is visual proof that a reaction layer
which suggest capillary stress gradients and shrinkage
was formed on the glass. The images in FIG. 5 show
that are characteristic of dehydration. This indicates 5
that the outer diameter (reaction layer/solution
that the corroded surface of the DyLAB-5 or DyLABinterface) of the DyLAB-10 glass microspheres
remained nearly constant and the reaction layer grew
10 glass was permeable to the PBS solution and
thicker as the glass/corrosion layer interface moved
mechanically weaker than the starting glass, probably
toward the center of each sphere. This gave the appear
due to a more open structure and porosity resulting
ance of a shrinking, spherical “core” within the DyLAB
from corrosion.
10
glass microspheres, which is believed to consist of the
(B) EDS Analysis
unreacted glass. The fact that the outer diameter of the
Cracks were also seen on the surface of the DyLAB-5 and
DyLAB glass microspheres did not change is a further
DyLAB-10 glass plates, pictured in FIGS. 4(a) and (b).
indication that the corrosion layer mostly consisted of
FIG. 4a also shows that a fraction of the corrosion layer
undissolved glass components rather than reprecipi
on the DyLAB-5 glass plate was separated from the 15
tated compounds.
glass that had been immersed in PBS at 37° C. for 11
(5) In Vivo Corrosion of DyLAB Glass Microspheres
days. From ICP analysis of the solution, it was not
A corrosion layer also formed on the surface of nonsurprising that the atomic ratio of Dy to A1 plus Si
radioactive DyLAB-10 glass microspheres (23 fim in aver
(Dy/Al+Si)), as determined by EDS, was 3.3 times
greater in the corrosion layer that separated from the 20 age diameter) that were injected into the healthy stifle joint
(knee) of a rat. Photomicrographs of the DyLAB-10 glass
DyLAB-5 glass than in the as-made DyLAB-5 glass.
microspheres imbedded in the synovial membrane, FIGS.
Since no detectable amount of Dy leached from the
6(a) and (b) (two weeks after injection), show evidence of
DyLAB glasses, the concentration of Dy in the cor
a corrosion layer, which is similar in appearance to the
roded glass was expected to increase as the other glass
corroded layer seen on the DyLAB-5 or DyLAB-10 glass
components dissolve in either PBS solution or deion 25 microspheres immersed in PBS solution at 22 or 37° C.
ized water. EDS analysis also revealed that Mg, a
Likewise, the size of the DyLAB-10 glass microspheres
component of the DyLAB glasses, was absent from the
injected into the rat did not decrease noticeably during two
corroded layer on the DyLAB-5 glass.
weeks in the stifle joint. None of the microspheres were
(C) XPS Analysis
found outside the synovial membrane (see FIG. 6(A)). There
The surface resolution of XPS analysis of glass is 10 to 20 30 was no discernable difference in the stifle joints injected with
A, compared to approximately one micron for EDS,
either 2 or 4 mg of DyLAB-10 glass microspheres.
and can be combined with ion sputter milling to give a
These results indicate that the corrosion testing in simu
lated body conditions is representative of the behavior of
compositional depth profile. The increasing size of the
ReLAB glass microspheres during in vivo use. There is little
peak caused by Dy in the XPS spectra (not shown)
indicates that the concentration of Dy in the DyLAB-10 35 reason to believe that the corrosion layer on the surface of
the DyLAB-10 glass microspheres injected into the rat was
glass increased as corrosion progressed. Based on the
appreciably different in composition than that which formed
size of the XPS peaks for B and Al, the concentration
on the surface of the DyLAB-5 or DyLAB-10 glass micro
of B and Al appears lower to a depth of 1000 and 80 A,
spheres immersed in deionized water or PBS solution. Thus,
respectively, in the DyLAB-10 glass immersed for 5 or
24 hours. The XPS peaks for B and Al in the 2 week 40 the corrosion layer that forms on DyLAB glass microspheres
imbedded in the synovial membrane would be expected to
DyLAB-10 glass sample most closely resemble those
retain most, if not all, of the Dy from the starting glass for
of as-made DyLAB-10 glass plate. The Dy concentra
at least two weeks after the spheres are injected, at which
tion appears to remain the same or to increase in the
time all of the microspheres are non-radioactive. This sug
DyLAB-10 glass even after 2 weeks of corrosion,
gests that none of the injected radioactivity from DyLAB or
rather than decrease as it would if Dy was being 45 HoLAB glass microspheres would escape, either in the form
dissolved from the glass.
of glass particulates or dissolved 165Dy or 166Ho, outside a
XPS analysis also revealed that phosphorus ions from the
human joint during radiation synovectomy.
PBS solution were present in the surface of the
Equally important is the fact that none of the injected
DyLAB-10 glass microspheres (=100,000 or 200,000
DyLAB-10 glass after immersion for 5, 24 or 336
hours. The XPS spectra for the samples immersed for 50 spheres/joint) were found outside the synovial sac. All of the
DyLAB-10 glass microspheres appeared to be imbedded in
5 or 24 hours show that the concentration of phospho
the synovial membrane. This is a critical observation since
rus decreased with depth but increased with dissolution
ReLAB glass microspheres can deliver a more uniform dose
time. This concentration gradient suggests that phos
of therapeutic radiation when located inside the synovial
phorus was diffusing into the corrosion layer and
possibly reacting with the undissolved glass compo 55 membrane.
The rat resumed normal activity immediately after the
nents rather than simply precipitating on the surface.
glass
microspheres were injected and did not show any
(D) Real Time Video Microscopy (RTVM)
negative response during the two weeks the microspheres
Reaction of the DyLAB glass microspheres is most viv
were in the stifle joints. There was no evidence of necrosis
idly shown by real time video microscopy (RTVM).
of the joint tissue or physical damage to the articular
RTVM clearly demonstrates that the size of the DyLAB 60 cartilage, shown in FIG. 6(a), one of the five criteria for in
glass microspheres does not decrease when the micro
vivo use of the RELAB glasses. A foreign body response
spheres begin to degrade in the PBS solution. The
was observed, and the DyLAB-10 glass microspheres were
chronological RTVM images in FIG. 5 of the DyLABengulfed by macrophages (phagocytes) which appear as an
10 glass microspheres in PBS solution (estimated
elliptical halo surrounding the microspheres. The macroph
SA/V<0.1 cm-1) at 22° C. illustrate the growth of a 65 ages are visible in FIGS. 6(a) and (b), but are most clearly
layer that starts at the outer surface of the microsphere
shown surrounding the DyLAB-10 glass microspheres pic
tured on FIG. 7. There was no evidence that the foreign body
and grows inward with increasing time. This “shell”
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response observed in the rat caused any harm to the joint,
and engulfment of the RELAB glass microspheres by mac
rophages may be beneficial, since it is considered one
Dy20 3
1.7 mole %
method whereby the glass microspheres can be removed
Li20
24.6 mole %
from the body when they are no longer radioactive.
5
b 2o 3
73.7 mole %.
In view of the above, it will be seen that the several
objects of the invention are achieved and other advantageous
4. A nonradioactive glass as set forth in claim 1 wherein
results attained.
said rare earth-lithium borate glass material has the followAs various changes could be made in the above compo
ing composition:
sitions and methods without departing from the scope of the 10
invention, it is intended that all matter contained in the
above description or shown in the accompanying drawings
Dy20 3
5 mole %
shall be interpreted as illustrative and not in a limiting sense.
Li20
16 mole %
What is claimed is:
a i 2o 3
5 mole %
15
1. A nonradioactive glass in particulate form adapted for
b 2o 3
66 mole %
s io 2
5 mole %
radiation therapy in a mammal comprising a biodegradable
MgO
3 mole %.
rare earth-lithium borate glass material having a composi
tion selected from the group consisting of:
20
xRE20 3.(100- a) LiB 30 5

5. A nonradioactive glass as set forth in claim 1 wherein
said rare earth-lithium borate glass material has the following composition:

xRE20 3.;yLi20.(100-3:-;y)B20 3
xRE2O3.yM gO .(100-x-y)L iB 3O5

25

ARE2O3._vMgO.(100-A-v)Li2B8O 13
xRE20 3.3 M g 0 .5 S i0 2.yAl20 3.(92-y-x)L i2B 80 13

wherein RE is a neutron activatable rare earth element
which, upon being subjected to an effective amount of
neutron irradiation, will produce a beta or gamma emitting
radioisotope, said radioisotope being distributed throughout
said glass material, x is the mole percent of RE20 3 and
ranges between approximately 0.5 and 5 and y is the mole
percent of Li20 , MgO or A120 3 and the balance is a lithium
borate material glass; wherein said lithium borate glass is
substantially free of lithium-6 and boron-10; and wherein
said glass upon being introduced into a body fluid for
radiation therapy is adapted to react therewith causing said
radioisotope to form an insoluble compound on the surface
of said glass material which is retained in said glass material
and thereby prevented from escaping from the treatment site.
2. A nonradioactive glass as set forth in claim 1 wherein
said beta or gamma emitting radioisotope is selected from
the group consisting of dysprosium-165, holmium-166,
yttrium-90, rhenium-186, rhenium-188 and samarium-153.
3. A nonradioactive glass as set forth in claim 1 wherein
said rare earth-lithium borate glass material has the follow
ing composition:
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Dy2o 3
Li20
a i 2o 3
b 2o 3
S i0 2
MgO

5
15
10
62
5
3

mole
mole
mole
mole
mole
mole

%
%
%
%

%
%.

6. A nonradioactive glass as set forth in claim 1 wherein
said glass is adapted for radiation synovectomy of arthritic
joints in a mammal and said glass is introduced into synovial
fluid for radiation synovectomy.
7. A nonradioactive glass as set forth in claim 1 wherein
said glass is spherical in shape.
8. A nonradioactive glass as set forth in claim 7 wherein
said glass is in the form of microspheres having a diameter
less than approximately 100 microns.
9. A nonradioactive glass as set forth in claim 8 wherein
said microspheres have a diameter between approximately 1
and 40 microns.
10. A nonradioactive glass as set forth in claim 1 wherein
said insoluble compound formed by said radioisotope is a
rare earth oxide.
11. A nonradioactive glass as set forth in claim 1 wherein
said radioisotope is dysprosium-165.
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